Department of Orthopaedic Surgery, Nippon Life Hospital, Osaka, Japan.
Department of Rehabilitation, Nippon Life Hospital, Osaka, Japan.
Mod Rheumatol. 2024 Aug 20;34(5):1013-1018. doi: 10.1093/mr/road111.
While biologics have been used for the patients with psoriatic arthritis, there remains to be unknown concerning long-term retention rates. This study aims to present real-world data about long-term retention rates of biologics for the patients with psoriatic arthritis, and to undertake an analysis of the contributing factors.
We examined retention rates and the reasons for discontinuation for biologics (adalimumab, certolizumab pegol, secukinumab, and ixekizumab) in 146 prescriptions (of which, 109 prescriptions were as naive) at our hospital since March 2010.
Throughout the entire course of the study, the 10-year retention rates were approximately 70% for adalimumab, 50% for ixekizumab, and 40% for secukinumab. When evaluating retention rates in the biologic-naïve subgroups, the 10-year retention rates were all approximately 70%. Regarding certolizumab pegol, the 3-year retention rate was approximately 75%. For adalimumab, a higher degree of arthritis at the initiation of treatment was found to correlate with an increased likelihood of secondary inefficacy. The main reason for discontinuation was secondary inefficacy, except for ixekizumab.
Each biologic exhibited a favourable long-term retention rate. The main reason for discontinuation was secondary inefficacy. Regarding adalimumab, secondary inefficacy was linked to the extent of arthritis upon treatment initiation.
虽然生物制剂已被用于治疗银屑病关节炎患者，但对于其长期保留率仍存在未知因素。本研究旨在提供关于生物制剂治疗银屑病关节炎患者长期保留率的真实世界数据，并对其影响因素进行分析。
我们回顾了自 2010 年 3 月以来我院 146 例（其中 109 例为初治）生物制剂（阿达木单抗、依那西普、司库奇尤单抗和依奇珠单抗）的保留率和停药原因。
在整个研究过程中，阿达木单抗的 10 年保留率约为 70%，依奇珠单抗约为 50%，司库奇尤单抗约为 40%。在评估生物制剂初治亚组的保留率时，10 年保留率均约为 70%。依那西普的 3 年保留率约为 75%。对于阿达木单抗，治疗开始时关节炎程度较高与继发无效率增加相关。除依奇珠单抗外，停药的主要原因为继发无效率。
每种生物制剂均表现出良好的长期保留率。停药的主要原因为继发无效率。对于阿达木单抗，继发无效率与治疗开始时关节炎的严重程度有关。
